Abstract 1066P
Background
Previous data suggest a negative impact of steroids (ST) in patients (pts) treated with immune checkpoint inhibitors (ICI), due to their immunosuppressive properties. How dosage and time of administration modulate this effect is yet to be clarified.
Methods
Retrospective study of pts who received ICI alone in a tertiary university hospital (2016-2022). For each pt, the daily dose of ST was collected (equivalent in mg/kg of prednisone) until progression of disease (PD) or death: 30 days before the 1st cycle (C1) (-30D), 30 days from C1 (D1-30), 3 months from C1 (D1-90) and after 6 months (m) from C1 (>D6m). We evaluated the impact of the cumulative dose (CD) of ST on the objective response rate (ORR), the disease control rate (DCR) and progression-free survival (PFS).
Results
We evaluated 475 pts (median age: 67.5) with advanced solid tumors (NSCLC: 33.9%; urothelial: 17.3%; renal: 13.7%; melanoma: 11.2%; head and neck: 11.0%; others: 12.9%) treated with anti-PD1 (64.4%), anti-PDL1 (20.4%), anti-PD1 plus anti-CTLA4 (13.3%) or anti-CTLA4 (1.9%); 42.1% in 1st line, 43.1% in 2nd line, 14.8% in further lines. Performance status (PS) prior to C1 was: 0 (31.0%), 1 (53.6%), ≥2 (15.4%). 48.2% of pts received ST during therapy with ICI (17.3% in -30D; 32.6% in D1-D90; 16.6% in >D6m). The ORR was significantly lower in pts who received ST in -30D (20.3% [95% CI 11.4-29.1%] vs 36.7% [95% CI 31.8-41.5%]; p<0.01) and in D1-90 (25.7% [95% CI 18.6-32.7%] vs 37.7% [95% CI 32.3-43.1%; p=0.01]). The negative impact of ST was confirmed by a multivariate analysis including PS, type of tumor, disease burden, type of ICI and line of treatment. There was an inverse correlation between the CD of ST in -30D and the DCR (no ST: 52.1%; Q1: 45%; Q2: 30.0%; Q3: 15.8%; Q4: 25%) (p<0.01). The impact of CD was confirmed in D1-30, but not in D1-90 and >D6m. Among pts without PD at 6 months, PFS tended to be longer in those who received ST (23.2 vs 17.6 m; p=0.065).
Conclusions
Our results demonstrate the negative impact of ST on the outcomes of ICI, even at low doses. This effect seems time and dose-dependent, prevailing in pts with an early exposure to ST (<3m) and proportional to cumulative dose only around the initiation of ICI (from -30D to D30).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A. Soria Rivas: Financial Interests, Institutional, Advisory Board: MSD, Novartis, Bristol, Roche, Merck, Sanofi Aventis. P. Garrido Lopez: Financial Interests, Institutional, Advisory Board: AstraZeneca, Bristol, Janssen, Lilly, Pfizer, Roche, Novartis, Rovi, Gilead, MSD, Takeda. P. Gajate Borau: Financial Interests, Institutional, Advisory Board: Astellas, Bristol Myers, Ipsen, Merck, Ipsen, Pfizer, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
1070P - Patterns of adverse reactions for immune checkpoint inhibitors in cancer patients with central nervous system metastases
Presenter: Tianqi Gu
Session: Poster session 19
1071P - Analysis of pulmonary adverse events associated with immune checkpoint inhibitors based on FAERS and VigiBase database
Presenter: Zimu Li
Session: Poster session 19
1072P - DuoBody-EpCAMx4-1BB mediates conditional T cell co-stimulation and promotes antitumor activity in preclinical models
Presenter: Sina Fellermeier-Kopf
Session: Poster session 19
1073P - Overcoming resistance to immunotherapy with FGFR inhibition in GU cancer models
Presenter: Ilya Tsimafeyeu
Session: Poster session 19
1074TiP - A phase I/II, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors
Presenter: Martin Gutierrez
Session: Poster session 19
1075TiP - A phase I/Ib open-label, first-in-human, single agent, dose escalation and expansion study of a HER2-targeted T cell engager (SAR443216) in patients with relapsed/refractory HER2-expressing solid tumors
Presenter: Ecaterina Dumbrava
Session: Poster session 19
1076TiP - First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors
Presenter: Sunil Babu
Session: Poster session 19
1077TiP - TAK-500 as a single agent and in combination with pembrolizumab in patients (pts) with advanced solid tumors: Rationale and design of a phase I/II study
Presenter: Harshabad Singh
Session: Poster session 19
1078TiP - Phase I/II, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101 (anti-VISTA) as monotherapy and in combination with cemiplimab in patients (pts) with advanced solid tumors
Presenter: Kyriakos Papadopoulos
Session: Poster session 19